135 completed, 10 recruiting, 7 unknown, 4 active not recruiting. 162 Phase 3, 7 Phase 2.
Follow Streptococcal Infections: new trials by email Literature Review of Streptococcal Infections trials Research Report on Streptococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Penicillin to Prevent Early Rheumatic Heart Disease in School-Aged Children Oral Penicillin V - Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | 9622 | 2027-02-01 | 2026-09-03 |
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial GBS-NN/NN2 vaccine, Placebo - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Not yet recruiting | Minervax ApS | 6600 | 2026-11-30 | 2026-11-06 |
| A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC) - Pneumococcal Disease | Phase 3 | Active not recruiting | Pfizer | 4701 | 2026-09-08 | 2026-11-12 |
| A Study to Evaluate 20vPnC in Healthy Chinese Infants 20vPnC, 13vPnC - Pneumococcal Diseases | Phase 3 | Recruiting | Pfizer | 1250 | 2026-07-25 | 2026-08-10 |
| Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 3 | Recruiting | Pfizer | 1200 | 2026-06-15 | 2026-10-26 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 3 | Recruiting | Pfizer | 3230 | 2026-05-29 | 2026-10-20 |
| A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 3 | Recruiting | Pfizer | 2400 | 2026-05-04 | 2026-11-06 |
| A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop Secondary Prophylaxis - Rheumatic Heart Disease | Phase 3 | Recruiting | Children's Hospital Medical Center, Cincinnati | 922 | 2026-03-23 | 2026-06-22 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination 31-valent pneumococcal conjugate vaccine, PCV20 - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 752 | 2026-02-09 | 2026-11-13 |
| Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age PCV21 vaccine, 20vPCV licensed vaccine - Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Recruiting | Sanofi | 2195 | 2026-01-20 | 2026-10-05 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 1390 | 2026-01-12 | 2026-11-13 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 4049 | 2025-12-01 | 2026-10-16 |
| A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) PCV13i, Prevnar 13 - Pneumococcal Infections, Streptococcal Infections | Phase 3 | Active not recruiting | CanSino Biologics Inc. | 600 | 2025-11-14 | 2026-08-05 |
| A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Active not recruiting | Minervax ApS | 137 | 2025-03-07 | 2026-09-04 |
| Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents PCV21, 20vPCV - Pneumococcal Infections | Phase 3 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 1268 | 2025-02-28 | 2025-10-06 |
| GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection | Phase 2 / Phase 3 | Withdrawn | Minervax ApS | 2024-12-17 | 2026-10-13 | |
| A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine pneumococcal disease prevention - Pneumococcal Vaccines, Pneumococcal Infections | Phase 3 | Recruiting | Beijing Minhai Biotechnology Co., Ltd | 500 | 2024-11-01 | 2025-03-24 |
| Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Sinovac PCV13, Prevnar® - Pneumococcal Infectious Disease | Phase 3 | Recruiting | Sinovac Life Sciences Co., Ltd. | 3080 | 2024-10-23 | 2026-01-28 |
| TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children Dexamethasone Oral, Placebo - Rheumatic Fever, Sydenham Chorea | Phase 3 | Recruiting | Starship Child Health, Te Toka Tumai Auckland | 80 | 2024-06-17 | 2025-06-24 |
Showing 20 of 162. Sign in to see all of them.
Pneumococcal Infections (115) · Pneumonia (11) · Rheumatic Heart Disease (9) · Impetigo (8) · Pneumonia, Pneumococcal (8) · Haemophilus Infections (7) · Otitis Media (7) · Acquired Immunodeficiency Syndrome (3) · Atrial Fibrillation (3) · Bacterial Infections (3) · Diphtheria (3) · HIV Infections (3) · Meningitis (3) · Mitral Valve Stenosis (3)
Bacterial Infections and Mycoses (161) · Infections (161) · Gram-Positive Bacterial Infections (160) · Bacterial Infections (159) · Respiratory Tract Diseases (23) · Lung Diseases (20) · Respiratory Tract Infections (20) · Pathological Conditions, Signs and Symptoms (11) · Skin and Connective Tissue Diseases (11) · Virus Diseases (11) · RNA Virus Infections (10) · Cardiovascular Diseases (9) · Gram-Negative Bacterial Infections (9) · Pneumonia (9)
13-valent pneumococcal vaccine (23) · 23-valent pneumococcal capsular polysaccharide vaccine (16) · PHiD-CV vaccine (15) · Heptavalent Pneumococcal Conjugate Vaccine (14) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (14) · Pneumococcal Vaccines (11) · RIX4414 vaccine (6) · 2,4,5,4'-tetrachlorodiphenylsulfoxide (5) · Hepatitis A Vaccines (5) · Hiberix (5) · Sodium Chloride (5) · Hepatitis B Vaccines (4) · 10-valent pneumococcal conjugate vaccine (3) · Chickenpox Vaccine (3) · Pentetic Acid (3)
GlaxoSmithKline (44) · Merck Sharp & Dohme LLC (33) · Pfizer (31) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (3) · Minervax ApS (3) · SK Chemicals Co., Ltd. (3) · Vaxcyte, Inc. (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · CanSino Biologics Inc. (2) · Children's Hospital Medical Center, Cincinnati (2) · Ferrer Internacional S.A. (2) · PATH (2) · Population Health Research Institute (2) · Sanofi Pasteur, a Sanofi Company (2) · Starship Child Health, Te Toka Tumai Auckland (2)
United States (45) · Poland (22) · Finland (17) · Spain (16) · Australia (15) · Germany (15) · Canada (12) · China (12) · France (12) · Japan (11) · South Korea (11) · Thailand (11) · Puerto Rico (10) · South Africa (10) · Sweden (10)
Amanda J Leach, PhD (2) · Du Lin, Master (2) · Edward K Mulholland, DM (2) · Jonathan R Carapetis, PhD (2) · Peter S Morris, PhD (2) · Ross M Andrews, PhD (2) · Ade Meidian Ambari, MD,FIHA (1) · An Aldia Asrial, MD (1) · Andrea Z Beaton, Dr (1) · Andrew J Pollard, BSc MBBS PhD MRCP FRCPCH (1)
PMID 25008901, PMID 25278086, PMID 30365584, PMID 34986178, PMID 36211411, PMID 36368038, PMID 37846456, PMID 41187484, PMID 11172176, PMID 14557958, PMID 19325447, PMID 19325451, PMID 19325452, PMID 19584345, PMID 20088694, PMID 20823436, PMID 20980796, PMID 21695210, PMID 21807056, PMID 21813135, PMID 21860256, PMID 23158882, PMID 23658394, PMID 23804191, PMID 24120678, PMID 24287186, PMID 24356787, PMID 24447437, PMID 24921688, PMID 25127244, PMID 25329446, PMID 25355940, PMID 25395187, PMID 25396674, PMID 25499011, PMID 25888646, PMID 26020101, PMID 26284652, PMID 26506438, PMID 26529076, PMID 27125273, PMID 27145999, PMID 27149114, PMID 27254028, PMID 27258647, PMID 27338143, PMID 27422342, PMID 28079828, PMID 28087146, PMID 28425818
2018 (13), 2019 (7), 2008 (3), 2017 (3), 2014 (2), 2023 (2), 2025 (2), 2005 (1), 2009 (1), 2015 (1)